Form
SCHEDULE 13G/A
Passive or exempt beneficial ownership filing.
BIOTECHNOLOGY VALUE FUND L P - 31 Mar 2026 SCHEDULE 13G/A Report for TENAX THERAPEUTICS, INC. Common Stock, $0.0001 par value per share (TENX)
- Filing manager
- BIOTECHNOLOGY VALUE FUND L P
- Reporting owner
- BVF PARTNERS L P/IL
- Beneficially owned shares
- 1,908,722 shares
- Large-stake signal
-
Ownership
10%Beneficial ownership of this reported class.
Shares
1,908,722 sharesShares beneficially owned as disclosed.
Event date
31 Mar 2026Date tied to the ownership event or amendment.
Accepted by SEC
15 May 2026EDGAR acceptance date.
How to read this large-stake filing
- Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
- Compare this filing with the holder history and issuer page before treating the percentage as a current position.
- Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
- Class ownership
- 10%
- Symbol
- TENX
- Shares outstanding
- 19,106,326 shares
- SEC form
- SCHEDULE 13G/A
- Accepted by SEC
- 15 May 2026, 16:13:58 UTC
- Event date
- 31 Mar 2026
- Prior SEC filing
- 17 Feb 2026
- Source filing
- View source filing
Ownership signal
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Subject security
Names, identifiers, and filing context for this profile.
2 source fields
Source evidence
Original filing metadata and source links for verification.
5 source fields
Key filing fact
BIOTECHNOLOGY VALUE FUND L P disclosed 10% ownership in TENAX THERAPEUTICS, INC. Common Stock, $0.0001 par value per share (TENX) on 31 Mar 2026.
Key facts
- BIOTECHNOLOGY VALUE FUND L P filed SCHEDULE 13G/A for TENAX THERAPEUTICS, INC. Common Stock, $0.0001 par value per share (TENX).
- Disclosed ownership: 10%.
- Date of event: 31 Mar 2026.
Change
- Previous schedule filing date: 17 Feb 2026.
- Current filing was accepted on 15 May 2026, 16:13.
Research use
- This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
- Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.
Evidence
Backed by Schedule 13D/13G
View source filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Disclosed reporting parties (10)
Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares owned | Sole voting power | Shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BIOTECHNOLOGY VALUE FUND L P | 9.2% | 1,754,719 | 0 | 1,754,719 | /s/ Mark N. Lampert | Mark N. Lampert, Authorized Signatory | |
| BVF I GP LLC | 9.2% | 1,754,719 | 0 | 1,754,719 | /s/ Mark N. Lampert | Mark N. Lampert, Authorized Signatory | |
| BIOTECHNOLOGY VALUE FUND II LP | 0.9% | 149,536 | 0 | 149,536 | /s/ Mark N. Lampert | Mark N. Lampert, Authorized Signatory | |
| BVF II GP LLC | 0.9% | 149,536 | 0 | 149,536 | /s/ Mark N. Lampert | Mark N. Lampert, Authorized Signatory | |
| Biotechnology Value Trading Fund OS LP | 0% | 0 | 0 | 0 | /s/ Mark N. Lampert | Mark N. Lampert, Authorized Signatory | |
| BVF Partners OS Ltd. | 0% | 0 | 0 | 0 | /s/ Mark N. Lampert | Mark N. Lampert, Authorized Signatory | |
| BVF GP HOLDINGS LLC | 10% | 1,904,255 | 0 | 1,904,255 | /s/ Mark N. Lampert | Mark N. Lampert, Authorized Signatory | |
| BVF PARTNERS L P/IL | 10% | 1,908,722 | 0 | 1,908,722 | /s/ Mark N. Lampert | Mark N. Lampert, Authorized Signatory | |
| BVF INC/IL | 10% | 1,908,722 | 0 | 1,908,722 | /s/ Mark N. Lampert | Mark N. Lampert, Authorized Signatory | |
| LAMPERT MARK N | 10% | 1,908,722 | 0 | 1,908,722 | /s/ Mark N. Lampert | Mark N. Lampert |
CIK / CUSIP context first